Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 2001;88:1044-1052
Published online before print May 10, 2001, doi: 10.1161/hh1001.090840
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
88/10/1044    most recent
hh1001.090840v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, J.
Right arrow Articles by Delafontaine, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, J.
Right arrow Articles by Delafontaine, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Thrombin
Right arrow Oxidant stress
Right arrow Cell signalling/signal transduction
Right arrow Growth factors/cytokines
Right arrow Smooth muscle proliferation and differentiation
(Circulation Research. 2001;88:1044.)
© 2001 American Heart Association, Inc.

Cellular Biology

Thrombin Regulates Insulin-Like Growth Factor-1 Receptor Transcription in Vascular Smooth Muscle

Characterization of the Signaling Pathway

Jie Du1, Marijke Brink1, Tao Peng, Bianca Mottironi, Patrick Delafontaine

From the Division of Nephrology (J.D.) and Department of Pathology (T.P.), Emory University, Atlanta, Ga; the Division of Cardiology (M.B., B.M.), University Hospital of Geneva, Geneva, Switzerland; and the Division of Cardiovascular Diseases (P.D.), University of Kansas, Kansas City, Kans.

Correspondence to Patrick Delafontaine, MD, Division of Cardiovascular Diseases, 1001 Eaton Building, Kansas University Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160. E-mail pdelafontaine{at}kumc.edu


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Abstract—We have previously demonstrated that thrombin upregulation of insulin-like growth factor-1 receptor (IGF-1R) is essential for thrombin-induced mitogenic signaling. To characterize the mechanisms involved, we studied transcription of the IGF-1R gene in rat aortic smooth muscle cells. Thrombin markedly increased IGF-1R mRNA levels, peaking at 3 hours (112±7% above control). This effect was mimicked by the hexapeptide SFFLRN (that functions as a tethered ligand) and was blocked by the thrombin inhibitor hirudin. Nuclear run-on assays indicated that thrombin stimulated IGF-1R gene transcription by 2.1-fold, and this was confirmed with the use of actinomycin D. Thrombin-mediated upregulation of IGF-1R mRNA and protein levels was protein kinase C independent but was completely inhibited by the protein tyrosine kinase inhibitor genistein and by the antioxidants N-acetyl-L-cysteine and pyrrolidinedithiocarbamate, suggesting the involvement of reactive oxygen species. The thrombin-induced increase in IGF-1R mRNA was inhibitable by diphenyleneiodonium chloride but not by other inhibitors of cellular oxidase systems, suggesting that NAD(P)H oxidase was necessary for the increase. Furthermore, inhibitors of the epidermal growth factor receptor kinase, Janus kinase-2 kinase, and Src kinase did not block the effect. Thus, thrombin transcriptionally regulates the IGF-1R gene via a redox-sensitive protein tyrosine kinase–dependent pathway that does not require protein kinase C activation. In view of our prior data indicating that IGF-1R density is a critical determinant of vascular smooth muscle cell growth, our findings have particular relevance to understanding mechanisms whereby growth factors such as thrombin regulate vascular proliferation in vivo.


Key Words: growth factors • signal transduction • gene regulation


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
The serine proteinase thrombin has multiple physiological effects.1 It is a procoagulant proinflammatory molecule2 3 4 5 and is a mitogen for vascular smooth muscle cells (VSMCs).6 7 8 Thrombin activates its receptor by a unique mechanism involving cleavage of the N-terminus of the receptor, generating a new N-terminus, which, in turn, acts as a tethered ligand.9 Cellular responses induced by thrombin are, in most cases, due to activation of protease-activated receptor (PAR)-1.1 PAR-1 is a proteolytically activated 7-transmembrane–spanning receptor that has been linked to a variety of cellular pathways, including hydrolysis of phosphoinositides, calcium mobilization, and activation of heterotrimeric G proteins, protein tyrosine kinases (PTKs), and monomeric G proteins.10 G-protein–coupled receptors, including the thrombin receptor, do not possess intrinsic tyrosine kinase activity. Using thrombin receptor–activating peptides and PTK inhibitors, some investigators have demonstrated that along with activation of its G-protein–coupled receptor, thrombin also requires PTK activity, possibly of a receptor type, for its mitogenic effect.11 12 13 Thus, thrombin has been shown to activate Src and c-Jun N-terminal kinase in VSMCs.14 15 16 Recently, evidence has been obtained indicating that thrombin exerts some of its effects by transactivating the epidermal growth factor (EGF) receptor.17

Insulin-like growth factor-1 (IGF-1) is a critical regulator of cell growth and differentiation.18 Its effects are mediated by the IGF-1 receptor (IGF-1R), a membrane tyrosine kinase. Evidence from a variety of studies using different cell types has shown that the IGF-1R is at a convergence point in the control of cell growth. Thus, a functional IGF-1/IGF-1R autocrine loop is required for the mitogenic effects of growth factors, such as platelet-derived growth factor,19 20 EGF,21 22 and angiotensin II (Ang II),23 and for cell transformation.24 Furthermore, the IGF-1R has been implicated in tumorigenesis.25 26

We have demonstrated that a functional IGF-1/IGF-1R pathway is essential for thrombin stimulation of VSMC mitogenesis.27 Thrombin upregulates VSMC IGF-1R, and inhibition of this effect using antisense phosphorothioate oligonucleotides inhibits thrombin-induced cellular proliferation. In addition, use of neutralizing anti–IGF-1 antibodies inhibits the mitogenic effects of thrombin. In the present study, we explored mechanisms and signaling pathways mediating the ability of thrombin to upregulate IGF-1R. Our findings indicate that thrombin regulates IGF-1R gene transcription via stimulation of its classic receptor, PAR-1, and that the signaling pathway is redox sensitive, requiring NAD(P)H oxidase and tyrosine kinase activity. These findings have important implications for understanding the mechanisms by which thrombin promotes cellular growth responses in vivo.


*    Materials and Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Materials and Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Cell Culture
VSMCs were isolated from rat thoracic aorta and grown as described.27 For experiments, cells from passages 5 to 16 were seeded into 100-mm dishes, grown to 80% to 90% confluence, and reached quiescence by exposure to defined serum-free medium (SFM) for 48 hours. Cells were then exposed to human thrombin (1 U/mL, 1000 U/mg) or to the rat thrombin receptor–specific peptide SFFLRN (100 µmol/L). The peptide was synthesized by the Microchemical Facility, Emory University, and purified by high-performance liquid chromatography. Some experiments were performed in the presence of the thrombin inhibitor hirudin (1 U/mL) or the transcriptional inhibitor actinomycin D (10 µg/mL).

Inhibition of ROS and PTKs
To determine the effects of reactive oxygen species (ROS) depletion, pyrrolidinedithiocarbamate (PDTC, 100 µmol/L) or N-acetyl-L-cysteine (NAC, 5 mmol/L) was applied 1 hour before exposing the cells to thrombin. In other experiments, cells were pretreated with diphenyleneiodonium chloride (DPI, 10 or 100 µmol/L), allopurinol (100 µmol/L), catalase (CAT, 500 U/mL), superoxide dismutase (SOD, 200 U/mL), or a combination of CAT and SOD for 1 hour before growth factor stimulation. To determine the effects of PTK inhibition, genistein (60 µmol/L) was applied 1 hour before exposing the cells to thrombin. To analyze the specific kinases involved, cells were pretreated with AG490 (10 to 50 µmol/L), AG1478 (10 to 50 µmol/L), PP1 (10 µmol/L), or PP2 (1 µmol/L) (all from Calbiochem).

Inhibition of PKC
To determine the effects of protein kinase C (PKC) downregulation, phorbol 12,13-dibutyrate (PDBu, 200 nmol/L) was added during the second 24-hour period of serum deprivation and maintained during the period of exposure to the agonist. A PKC inhibitor, bisindolylmaleimide (50 nmol/L) or chelerythrine (3 mmol/L), was applied at time 0 after 48-hour serum deprivation, immediately before the cells were exposed to the agonist. Concentrations of PKC inhibitors were at least 3 times the IC50 values for these compounds.28

IGF-1R mRNA Levels
Control and inhibitor-treated cells were exposed to SFM without or with thrombin or SFFLRN for 3 hours, total RNA was extracted with the use of TRI-reagent (Molecular Research Center), and IGF-1R mRNA levels were determined by solution hybridization/RNase protection assays with a radiolabeled antisense probe transcribed from a rat IGF-1R cDNA.29 The full-length probe is 251 bp, and the protected fragment is 195 bp. GAPDH or 18S riboprobes were included as a control, giving 133- and 158-bp protected bands, respectively. Autoradiograms of protected bands were quantified by densitometry.

Radioligand Binding Assays, Immunoblotting, and Measurement of DNA Synthesis
To determine the effect of thrombin on IGF-1R number and binding affinity, quiescent VSMCs were exposed to SFM without or with thrombin or SFFLRN for 24 hours. The dependence of thrombin upregulation of IGF-1R on PKC and ROS was determined by coincubating the cells with thrombin and inhibitors for 24 hours before the binding assays. Binding assays were performed and analyzed as described previously.29

To analyze the effect of kinase inhibitors on IGF-1R protein expression and DNA synthesis, quiescent VSMCs were incubated with an inhibitor for 1 hour before the administration of growth factors. After 16 hours, proteins were collected for analysis of IGF-1R by Western blotting.30 DNA synthesis was measured at 16 hours by adding [3H]thymidine (1 µCi/mL) during the last 4 hours of incubation. Samples were processed as described previously.29

Nuclear Run-On Transcriptional Analysis
These assays were performed as previously described,31 with modifications. Briefly, quiescent VSMCs were exposed to SFM in the presence or absence of thrombin for 3 hours. Nuclei were isolated with the use of a sucrose gradient, and transcription was carried out with the use of 2 to 5x107 nuclei in a 300-µL reaction mixture containing 37 mmol/L Tris-HCl, pH 8.0, 26% glycerol, 5.5 mmol/L MgCl2, 0.066 mmol/L EDTA, 140 mmol/L KCl, 0.1 mmol/L each ATP, GTP, and CTP, and 20 µL [{alpha}-32P]UTP (3000 Ci/mmol, Du Pont–New England Nuclear). RNA was extracted, and unincorporated nucleotides were separated by using Bio-Gel P-30 columns. Plasmids containing cDNAs for the IGF-1R (-610 to +200 bp relative to ATG), GAPDH (1.2-kb fragment), Ang II type 1 receptor (full-length rat sequence), and plasmid without insert (pGEM3) were linearized, denatured, and applied to a nylon membrane with use of a Bio-Rad slot-blot apparatus. After prehybridization in 100 mmol/L TES-HCl, pH 7.4, 0.2% SDS, 10 mmol/L EDTA, 0.3 mol/L NaCl, 1x Denhardt’s solution, and 100 µg/mL yeast tRNA, the membrane was hybridized in the same solution containing 1 to 5x106 cpm/mL of 0.2 mol/L NaOH treated 32P-labeled nuclear RNA for 40 hours at 65°C. Membranes were washed twice in 2x SSC and 0.1% SDS at room temperature and then in 0.1x SSC and 0.1% SDS for 2 hours at 65°C. Autoradiographic signals were quantified by densitometry.

Statistical Analysis
All experiments were performed at least 3 times. Data are expressed as mean±SE. Analysis of repeated measures was performed by ANOVA. Comparison between groups was performed by using a protected Tukey t test or Student t test when appropriate.

Materials
Thrombin, PDBu, CAT, allopurinol, and NAC were purchased from Sigma Chemical Co. Bisindolylmaleimide, chelerythrine, and genistein were from LC Laboratories, Alexis Corp. PDTC was from Fluka Chemical Corp. DPI, SOD, PP1, PP2, AG490, and AG1478 were from Calbiochem. TRI-reagent was from Molecular Research Center. The 18S riboprobe was from Ambion.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 *Results
down arrowDiscussion
 down arrowReferences
 
Effects of Thrombin on IGF-1R mRNA Levels
Exposure of VSMCs to thrombin caused a marked increase in IGF-1R mRNA levels (Figure 1ADown). To assess the time course of induction in IGF-1R expression, IGF-1R and GAPDH mRNAs were measured after exposure to an agonist for 0 to 24 hours. Thrombin induction of IGF-1R mRNA peaked at 3 hours (2.1-fold increase, P<0.0001; n=8), and levels were still elevated at 24 hours (P<0.01, Figure 1BDown). Thrombin caused a more delayed increase in GAPDH mRNA (P<0.01 at 24 hours). To determine whether the effect was mediated via proteolytic activation of the thrombin receptor, we measured IGF-1R mRNA after exposure to the hexapeptide SFFLRN, which acts as a tethered ligand after cleavage of the amino terminus of the thrombin receptor. SFFLRN increased IGF-1R mRNA by 47% (P<0.001, n=6), mimicking the effect obtained with the parent agonist thrombin (Figure 1CDown). To further demonstrate that the effect was mediated by a receptor-dependent mechanism, we blocked the binding of thrombin to its receptor with hirudin, which resulted in complete inhibition of the induction of IGF-1R mRNA (P<0.01, Figure 1DDown).



View larger version (18K):
[in this window]
[in a new window]
  		Figure 1. Effect of thrombin and SFFLRN on IGF-1R mRNA levels. A, Representative solution hybridization autoradiogram. Total RNA from thrombin-treated VSMCs (3 hours) was hybridized to IGF-1R and GAPDH riboprobes and RNAse-digested, and protected bands were detected after sequencing gel electrophoresis. B, Densitometric analysis of time course of changes in IGF-1R. Shown is the percent increase in mRNA in thrombin-exposed cells over levels in cells in SFM. C, Solution hybridization analysis showing the effect of SFFLRN (3 hours) on IGF-1R mRNA (3 representative experiments). D, Solution hybridization analysis showing the effect of the antithrombin agent hirudin (representative experiment).

Effects of Thrombin on Newly Transcribed IGF-1R mRNA
To determine whether the increase in IGF-1R mRNA was transcriptionally mediated, we performed in vitro transcription with the use of nuclei from VSMCs treated without or with thrombin for 3 hours. Hybridization of radiolabeled nuclear RNA probes to IGF-1R cDNA demonstrated a 2.1-fold increase in IGF-1R signal from thrombin-stimulated cells (n=4, P<0.05, Figure 2Down). There was a small (1.25-fold) increase between nuclear transcripts from control or agonist-exposed cells after hybridization to GAPDH cDNA (n=5, P=0.13). Hybridization to the Ang II type 1A receptor cDNA gave a significant 2-fold decrease in signal intensity (n=4, P<0.025), consistent with a prior study indicating that thrombin decreases Ang II receptor expression.32 Vector alone gave a minimal signal. To confirm that thrombin induces IGF-1R gene transcription, we inhibited RNA synthesis with actinomycin D, resulting in complete loss of the upregulation of IGF-1R mRNA (Figures 3ADown and 3BDown) and protein (Figure 3CDown) levels by thrombin.



View larger version (23K):
[in this window]
[in a new window]
  		Figure 2. Nuclear run-on analysis. A, Representative autoradiogram. Quiescent VSMCs were incubated in SFM with or without thrombin for 3 hours. Nuclei were isolated, and 32P-labeled nuclear RNA transcripts were hybridized to IGF-1R, GAPDH, Ang II type 1A receptor (AT1AR), or pGEM. B, Densitometric analysis of nuclear run-on autoradiograms. Shown is the percent increase in signal from thrombin-treated cells over signal from cells in SFM (n=4).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 3. Actinomycin D blocks thrombin-induced IGF-1R expression. A, Representative solution hybridization autoradiogram from cells incubated with thrombin and actinomycin D. B, Densitometric analysis showing that actinomycin D inhibits thrombin-induced increases in IGF-1R mRNA at 3 hours (n=8). C, Radioligand binding assays indicating that actinomycin D blocks the ability of thrombin to increase IGF-1R protein at 24 hours (n=2).

Effect of PKC Downregulation on Thrombin-Induced IGF-1R Expression
PKC activation is an important signaling pathway for the cellular effects of multiple mitogens.33 34 To define the PKC dependence of thrombin regulation of IGF-1R, we measured IGF-1R mRNA levels after 24 hours of preincubation with the phorbol ester PDBu. Chronic exposure to PDBu has been shown to downregulate PKC activity in VSMCs by 80% to 90%.35 After preexposure to PDBu, thrombin still increased IGF-1R mRNA (1.7-fold increase, P<0.025; n=6) and binding (1.5-fold increase, P<0.05; n=4) levels (Figure 4ADown). To further define the PKC dependence of the effect, we used 2 structurally unrelated inhibitors of PKC (Figure 4BDown). Thrombin still increased IGF-1R mRNA by 2.0-fold in the presence of bisindolylmaleimide (n=5, P<0.05) or chelerythrine (n=5, P<0.05). A small increase in IGF-1R mRNA was observed with the inhibitors alone (P=NS). Furthermore, thrombin upregulated the IGF-1R number by 1.8-fold in the presence of bisindolylmaleimide (n=4, P<0.05) and by 1.5-fold in the presence of chelerythrine (n=4, P<0.025), without altering IGF-1R binding affinity (Kd) (not shown).



View larger version (30K):
[in this window]
[in a new window]
  		Figure 4. Thrombin regulation of IGF-1R expression is PKC independent. A, Effect of PDBu. Top, Representative solution hybridization autoradiogram. After 24 hours of incubation with PDBu, VSMCs were treated with thrombin for 3 hours. Middle, Densitometric analysis of IGF-1R mRNA levels in PDBu- and thrombin-treated cells (n=6). Values were normalized for GAPDH levels. Bottom, IGF-1R radioligand binding. After 24 hours of incubation with PDBu, VSMCs were incubated in SFM in the continued presence of PDBu with or without thrombin for 24 hours, and binding assays were performed (n=4). B, Effect of bisindolylmaleimide and chelerythrine. Top, Representative solution hybridization autoradiogram. VSMCs were incubated with PKC inhibitors and thrombin for 3 hours before RNA extraction and analysis. Middle, Densitometric analysis of IGF-1R mRNA (n=5). Bottom, IGF-1R radioligand binding performed after 24 hours of incubation with PKC inhibitors and thrombin (n=4).

Effect of Inhibition of ROS on Thrombin-Induced IGF-1R Expression
We have previously shown that Ang II induces IGF-1R transcription in VSMCs through a redox-sensitive pathway.36 To test whether the action of thrombin to increase the IGF-1R is mediated through ROS, we determined the inhibitory effect of the antioxidant PDTC (Figure 5ADown) or NAC (Figure 5BDown). Both compounds completely inhibited the induction of IGF-1R mRNA. The findings for NAC were confirmed in radioligand binding assays. Thrombin increased the IGF-1R number 1.8-fold at 24 hours (n=6, P<0.01), and this increase was inhibited by NAC (Figure 5BDown). Scatchard analysis indicated no significant changes in IGF-1R binding affinity: Kd control, 4.7±0.1 nmol/L; Kd thrombin, 5.5±0.4 nmol/L; Kd NAC, 4.8±0.3 nmol/L; and Kd NAC+thrombin, 7.1±1.0 nmol/L (n=5, P=NS). These findings strongly suggest that an oxidant signal was required for thrombin induction of IGF-1R transcription.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 5. Effect of ROS inhibition on thrombin stimulation of IGF-1R. A, Effect of PDTC. Left, Representative solution hybridization autoradiogram. Quiescent VSMCs were incubated with thrombin and PDTC for 3 hours before RNA extraction and analysis. Right, Densitometric analysis of IGF-1R mRNA, normalized for GAPDH (n=5). B, Effect of NAC. Left, Representative solution hybridization autoradiogram. VSMCs were exposed to thrombin and NAC for 3 hours before RNA extraction and analysis. Middle, Densitometric analysis of IGF-1R mRNA, normalized for GAPDH (n=5). Right, Binding assays. Quiescent VSMCs were exposed to thrombin and/or NAC for 24 hours, when radioligand binding assays were performed (n=6).

ROS-producing systems include various NADPH and NADH oxidases, xanthine oxidase, and NO synthase. We examined the effects of inhibitors of different oxidase systems on the thrombin-induced increase in IGF-1R. This increase was completely blocked by DPI at 100 µmol/L (n=5, P<0.05), an inhibitor of flavoprotein-containing enzymes, such as NAD(P)H oxidase (Figure 6Down). DPI alone had negligible effects on IGF-1R mRNA levels in the absence of thrombin. No inhibition was observed with allopurinol, which is an inhibitor of xanthine oxidase (data not shown), with CAT, which blocks the production of the reactive oxygen intermediate H2O2, with superoxide dismutase, which blocks the reactive oxygen intermediate O2 · -, or with a combination of CAT and SOD (Figure 6Down). Taken together, these results indicate that the NAD(P)H oxidase system is involved in the response to thrombin.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 6. Densitometric analysis of the effect of ROS inhibitors on thrombin-induced upregulation of IGF-1R mRNA. VSMCs were preincubated with DPI, SOD, or CAT for 1 hour and then incubated with thrombin for 3 hours before RNA extraction and analysis. All IGF-1R mRNAs were normalized for 18S (n=3 or 4).

Effect of PTK Inhibition on Thrombin-Induced IGF-1R Expression
Thrombin activates several PTKs, which may be important in its signaling cascade, including nonreceptor tyrosine kinases, such as Src14 and focal adhesion kinase,37 and receptor tyrosine kinases, such as the IGF-1 receptor38 and the EGF receptor.39 To study the role of PTK in thrombin-induced IGF-1R transcription, VSMCs were treated with genistein. The induction of IGF-1R mRNA by thrombin (2.8-fold increase, P<0.00001; n=5) was completely blocked by genistein (Figures 7ADown and 7BDown). Furthermore, the ability of SFFLRN to increase IGF-1R mRNA (1.5-fold increase, P<0.001; n=6) was inhibited by genistein (Figure 7CDown). We further confirmed the requirement of PTK in thrombin upregulation of IGF-1R by measuring IGF-1R numbers. In these experiments, thrombin upregulated the IGF-1R number by 1.8-fold (n=4, P<0.01), and genistein completely inhibited this effect (Figure 7DDown). These data demonstrate that PTKs are required for thrombin stimulation of IGF-1R expression.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 7. PTK inhibitor blocks thrombin- and SFFLRN-induced upregulation of IGF-1R. A, Representative solution hybridization autoradiogram is shown. VSMCs were incubated with thrombin and genistein for 3 hours before RNA extraction and analysis. B, Densitometric analysis of IGF-1R mRNA is shown normalized for GAPDH (n=5). C, Genistein inhibits the ability of SFFLRN (3 hours) to increase IGF-1R mRNA. D, Radioligand binding studies performed after 24 hours of incubation with thrombin and genistein (n=4).

To obtain insight into the specific PTKs involved, we studied the effects of inhibitors of receptor and nonreceptor kinases. Thrombin has been shown to transactivate the EGF receptor.17 However, the selective EGF receptor kinase inhibitor AG1478 did not abolish the induction of IGF-1R mRNA or protein by thrombin at 10, 20, or 50 µmol/L (Figure 8Down), concentrations that have been shown effective in inhibiting Ang II–induced extracellular signal–regulated kinase activation in rat VSMCs.40 As expected, the induction of IGF-1R mRNA and protein by EGF was inhibited by AG1478 (Figures 8ADown and 8BDown). Furthermore, the EGF-induced increase in [3H]thymidine incorporation was significantly inhibited by 50 µmol/L AG1478 (Figure 8CDown), confirming activity of the drug.



View larger version (43K):
[in this window]
[in a new window]
  		Figure 8. Effect of specific kinase inhibitors on growth factor–induced upregulation of IGF-1R mRNA (A), protein (B), and DNA synthesis (C). A, Densitometric analysis of IGF-1R mRNA levels after stimulation with thrombin, bFGF, or EGF in the presence or absence of the EGF receptor kinase inhibitor AG1478, the JAK-2 inhibitor AG490, or the Src kinase inhibitor PP1 (n=4 or 5). B, Representative Western blots. VSMCs were stimulated with thrombin (Thr), bFGF, or EGF in the presence or absence of AG1478, AG490, or PP1. C, Summary of data measuring [3H]thymidine incorporation in response to agonists in the presence or absence of kinase inhibitors (n=4).

The Janus kinase (JAK)-2 inhibitor AG490 had no effect on thrombin-induced increases of IGF-1R mRNA, protein, or DNA synthesis at doses of 10, 20, and 50 µmol/L. This inhibitor also failed to block induction of the IGF-1R by basic fibroblast growth factor (bFGF) (not shown) or EGF (Figures 8AUp and 8BUp). In a [3H]thymidine incorporation assay, AG490 significantly reduced the thrombin- and EGF-induced increases in DNA synthesis (P<0.01), demonstrating that the compound was active.

Furthermore, we studied the effects of Src kinase inhibitors. In these experiments, the increase in IGF-1R mRNA levels was slightly enhanced after incubation with PP1 before thrombin treatment (Figure 8AUp). The same results were obtained with PP2 (not shown). bFGF significantly increased IGF-1R mRNA and protein, and this increase was not inhibited by PP1 (Figures 8AUp and 8BUp); however, PP1 significantly reduced bFGF-induced increases in DNA synthesis (Figure 8CUp).


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 *Discussion
down arrowReferences
 
It has been demonstrated that the ability of thrombin to upregulate IGF-1R is a critical determinant of its mitogenic effects on VSMCs.27 Thus, use of IGF-1R gene–specific antisense oligonucleotides or of an anti–IGF-1 antibody blocks thrombin-induced DNA synthesis. In the present study, we demonstrate that the ability of thrombin to upregulate IGF-1R on VSMCs is mediated by transcriptional activation of the IGF-1R gene, resulting in a rapid increase in IGF-1R mRNA levels, with a peak at 3 hours that was maintained for at least 24 hours. The effect is transduced by the classic PAR-1, inasmuch as it is mimicked by the PAR-1–specific peptide SFFLRN. We further examined pathways whereby the G-protein–coupled receptor agonist thrombin increases expression of the tyrosine kinase IGF-1R.

A variety of signaling events are induced by thrombin. These include stimulation of PTK and PKC and activation of multiple intracellular kinases and phosphatases.1 10 12 Because PKC is postulated to be an important mediator of the effects of multiple growth factors, we assessed its role in thrombin regulation of IGF-1R mRNA. Chronic stimulation of PKC by incubation with PDBu results in marked downregulation of PKC activity.35 In this condition, thrombin caused a further significant 1.7-fold increase in IGF-1R mRNA and 1.5-fold increase in IGF-1R protein levels, suggesting that thrombin induces IGF-1R transcription via a PKC-independent pathway. To confirm this, we used 2 structurally unrelated PKC inhibitors, but in all cases, the stimulatory effect of thrombin on IGF-1R was retained. It is of note that atypical PKC isoforms (eg, PKC{zeta}) lack a phorbol ester binding site and are not downregulated by PDBu treatment.33 34 However, the failure of 2 different PKC inhibitors (and in particular, chelerythrine, which blocks the catalytic domain28 ) to block thrombin-induced increases in IGF-1R mRNA and protein argues against an involvement of PKC. Thus, the present findings are consistent with a PKC-independent pathway whereby thrombin stimulates IGF-1R expression.

To further define the potential mechanisms involved in thrombin regulation of IGF-1R, we studied the role of oxidant stress. Our findings show that the antioxidants PDTC and NAC suppress thrombin stimulation of IGF-1R expression. Patterson et al41 have recently shown that thrombin induces the generation of ROS in VSMCs at least in part through activation of NAD(P)H oxidase and that blocking this enzyme with DPI inhibits thrombin-induced proliferation. Consistently, we have demonstrated in the present study that DPI blocks the induction of IGF-1R by thrombin. Thus, unlike Ang II,36 thrombin activation of NAD(P)H oxidase provides a mechanism whereby activation of the thrombin receptor could lead to IGF-1R transcription. Again, unlike Ang II, the ability of thrombin to upregulate IGF-1R was not blocked by CAT. SOD also did not block the ability of thrombin to regulate IGF receptors. This lack of effect may be due to ineffective scavenging of intracellular reactive oxygen intermediates, or other intermediates may play a role.42

Recent studies have shown that PAR-1 couples functionally to multiple heterotrimeric G proteins that activate the mitogen-activated protein kinase (MAPK) pathway via the small GTP-binding protein p21ras.37 43 44 45 46 In various cell types, thrombin activation of the Ras/MAPK cascade requires non–receptor-dependent tyrosine kinase activity, such as Src44 46 or focal adhesion kinase,45 or receptor-dependent tyrosine kinase activity, eg, through the EGF receptor, which is transactivated by thrombin in rat 1 fibroblasts45 and in VSMCs.17 Although PKC activation provides a potential Ras-independent pathway whereby G-protein–coupled receptors may activate the MAPK pathway, our data using PDBu and PKC inhibitors argue strongly against the possibility that thrombin upregulation of IGF-1R uses PKC. To examine the potential role of PTK in the signal leading to IGF-1R transcription, we determined the effects of genistein. This tyrosine kinase inhibitor blocked the ability of thrombin to increase IGF-1R mRNA and protein levels. To determine which specific tyrosine kinases are involved, we determined the effect of Src, EGF receptor kinase, and JAK-2 kinase inhibitors. None of the inhibitors tested blocked IGF-1R induction by thrombin. JAK-2 is also not involved in IGF-1R induction by bFGF or EGF, indicating that JAK-2 is not required for IGF-1R regulation. However, growth factor–induced DNA synthesis was blocked by AG490, suggesting that JAK-2 is involved downstream from the IGF-1R. Taken together with our data using genistein, our results indicate that a kinase other than Src, EGF receptor, or JAK-2 must be involved in thrombin regulation of the IGF-1R.

Significant data have established that the IGF-1/IGF-1R autocrine loop is a critical regulator of the cell cycle. Thus, fibroblasts from mice expressing a null mutation for the IGF-1R gene have a marked reduction in their growth rate in serum.24 Normal growth cannot be restored by exposure to other growth factors but can be corrected by expression of the IGF-1R. A functional IGF-1/IGF-1R pathway is essential for the growth response to other growth factors, such as EGF,21 22 platelet-derived growth factor,19 20 and thrombin.27 Furthermore, simian virus 40 T-antigen transformation of cells requires a functional IGF-1R.47 It is of note that the effects of growth factors on IGF-1R expression may be critical in allowing cells to subsequently respond to endogenously synthesized IGF-1. Thus, in VSMCs, Ang II–induced and thrombin-induced mitogenesis is blocked by antisense phosphorothioate oligonucleotides targeting the IGF-1R mRNA.48 49 Furthermore, in VSMCs transfected with an IGF-1R antisense expression plasmid, growth responses are markedly blunted.29 In these cells, as in cells exposed to antisense oligonucleotides targeting the IGF-1R mRNA,49 there is a reduction in IGF-1R density of {approx}50%. Therefore, relatively small changes in IGF-1R density appear to be critical for the regulation of VSMC growth. We have previously shown that thrombin doubles IGF-1R density on VSMCs and that this is a critical requirement for thrombin-induced DNA synthesis. Our present study has defined the signaling cascade involved. It is important to emphasize that the IGF-1R gene promoter lacks TATA or CAAT motifs and that transcription starts from a unique "initiator" sequence.50 It will be of paramount importance to determine how transcription factors interact with this receptor promoter and, specifically, to determine whether thrombin regulates transcription via a common cis-acting sequence.

In summary, we have demonstrated that thrombin upregulates IGF-1R via PAR-1–mediated transcriptional activation of the IGF-1R gene. Thrombin-dependent regulation of IGF-1R is mediated via a PKC-independent pathway that is redox sensitive and involves the activation of NAD(P)H oxidase. It requires a tyrosine kinase activity other than Src, EGF receptor, or JAK-2. In view of the critical role played by the IGF-1R in mediating the growth effects of thrombin, these findings are particularly relevant to understanding biochemical pathways required for thrombin stimulation of cellular proliferative responses.


*    Acknowledgments
 
This study was supported by National Institutes of Health Grants HL-47035, HL-45317, and DK-45215; an American Heart Association Scientist Development Award (J.D.); the Swiss Cardiology Foundation; Swiss National Science Foundation Grant FNSR 3100-050799.97; and the Gerbex-Bourget Foundation. We are grateful to M. Burkhard for her excellent editorial assistance.


*    Footnotes
 
Original received December 29, 1999; resubmission received March 27, 2001; accepted March 29, 2001.

1 Both authors contributed equally to this study. Back


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin "talks" to cells: molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol. 1998;18:514–518.
  2. Fenton JW II. Regulation of thrombin generation and functions. Semin Thromb Hemost. 1988;14:234–240.
  3. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW II. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 1983;220:728–731.
  4. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest. 1989;84:1096–1104.
  5. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989;264:7768–7771.
  6. Graham DJ, Alexander JJ. The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg. 1990;11:307–312.
  7. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW II, Wilner GD, Vlodavsky I. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul. 1990;1:453–463.
  8. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94–98.
  9. Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest. 1992;89:351–355.
  10. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J. 1996;313:353–368.
  11. Weiss RH, Maduri M. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. J Biol Chem. 1993;268:5724–5727.
  12. Van Obberghen-Schilling E, Vouret-Craviari V, Chen YH, Grall D, Chambard JC, Pouyssegur J. Thrombin and its receptor in growth control. Ann N Y Acad Sci. 1995;766:431–441.
  13. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci. 1999;20:408–412.
  14. Chen YH, Pouyssegur J, Courtneidge SA, Van Obberghen-Schilling E. Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. J Biol Chem. 1994;269:27372–27377.
  15. Mitsui H, Maruyama T, Kimura S, Takuwa Y. Thrombin activates two stress-activated protein kinases, c-Jun N-terminal kinase and p38, in HepG2 cells. Hepatology. 1998;27:1362–1367.
  16. Collins LR, Minden A, Karin M, Brown JH. G{alpha}12 stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac. J Biol Chem. 1996;271:17349–17353.
  17. Kalmes A, Vesti BR, Daum G, Abraham JA, Clowes AW. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res. 2000;87:92–98.
  18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34.
  19. Clemmons DR, Van Wyk JJ. Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest. 1985;75:1914–1918.
  20. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A. 1979;76:1279–1283.
  21. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A, Baserga R. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 1992;3:199–205.
  22. Coppola D, Ferber A, Miura M, Sell C, D’Ambrosio C, Rubin R, Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 1994;14:4588–4595.
  23. Delafontaine P, Lou H. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem. 1993;268:16866–16870.
  24. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994;14:3604–3612.
  25. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 1995;55:249–252.
  26. Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog. 1997;8:71–92.
  27. Delafontaine P, Anwar A, Lou H, Ku L. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest. 1996;97:139–145.
  28. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990;172:993–999.
  29. Du J, Delafontaine P. Inhibition of vascular smooth muscle cell growth through antisense transcription of a rat insulin-like growth factor I receptor cDNA. Circ Res. 1995;76:963–972.
  30. Scheidegger KJ, Du J, Delafontaine P. Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor. J Biol Chem. 1999;274:3522–3530.
  31. Groudine M, Peretz M, Weintraub H. Transcriptional regulation of hemoglobin switching in chicken embryos. Mol Cell Biol. 1981;1:281–288.
  32. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995;48:601–609.
  33. Lee MW, Severson DL. Signal transduction in vascular smooth muscle: diacylglycerol second messengers and PKC action. Am J Physiol. 1994;267:C659–C78.
  34. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J. 1993;291:329–343.
  35. Stassen FL, Schmidt DB, Papadopoulos M, Sarau HM. Prolonged incubation with phorbol esters enhanced vasopressin-induced calcium mobilization and polyphosphatidylinositol hydrolysis of vascular smooth muscle cells. J Biol Chem. 1989;264:4916–4923.
  36. Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol. 1999;19:2119–2126.
  37. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts: Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem. 1997;272:31648–31656.
  38. Rao GN, Delafontaine P, Runge MS. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-{gamma}1 in rat aortic smooth muscle cells. J Biol Chem. 1995;270:27871–27875.
  39. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557–560.
  40. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273:8890–8896.
  41. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814–19822.
  42. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol. 2000;20:1430–1442.
  43. Lefkowitz RJ. G protein-coupled receptors, III: new roles for receptor kinases and ß-arrestins in receptor signaling and desensitization. J Biol Chem. 1998;273:18677–18680.
  44. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem. 1998;273:1839–1842.
  45. Della Rocca GJ, Maudsley S, Daaka Y, Lefkowitz RJ, Luttrell LM. Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade: role of focal adhesions and receptor tyrosine kinases. J Biol Chem. 1999;274:13978–13984.
  46. Ellis CA, Malik AB, Gilchrist A, Hamm H, Sandoval R, Voyno-Yasenetskaya T, Tiruppathi C. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway. J Biol Chem. 1999;274:13718–13727.
  47. Porcu P, Ferber A, Pietrzkowski Z, Roberts CT, Adamo M, LeRoith D, Baserga R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin-like growth factor 1 with its receptor. Mol Cell Biol. 1992;12:5069–5077.
  48. Gunther S, Alexander RW, Atkinson WJ, Gimbrone MA Jr. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol. 1982;92:289–298.
  49. Delafontaine P, Meng XP, Ku L, Du J. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides: effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem. 1995;270:14383–14388.
  50. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16:143–163.



This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. Cheng and J. Du
Mechanical Stretch Simulates Proliferation of Venous Smooth Muscle Cells Through Activation of the Insulin-Like Growth Factor-1 Receptor
Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1744 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Delafontaine, Y.-H. Song, and Y. Li
Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels
Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 435 - 444.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
T. Minami, Md. R. Abid, J. Zhang, G. King, T. Kodama, and W. C. Aird
Thrombin Stimulation of Vascular Adhesion Molecule-1 in Endothelial Cells Is Mediated by Protein Kinase C (PKC)-delta -NF-kappa B and PKC-zeta -GATA Signaling Pathways
J. Biol. Chem., February 21, 2003; 278(9): 6976 - 6984.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
88/10/1044    most recent
hh1001.090840v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, J.
Right arrow Articles by Delafontaine, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, J.
Right arrow Articles by Delafontaine, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Thrombin
Right arrow Oxidant stress
Right arrow Cell signalling/signal transduction
Right arrow Growth factors/cytokines
Right arrow Smooth muscle proliferation and differentiation

Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.